Diabetes MellitusNCT03034759
A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D
A study testing individualized insulin sensitivity index (ISind) in people with Diabetes Mellitus, run by Yale University at 1 site in United States.
Trial summary
We aim to test the efficacy of a new method for determining individual insulin sensitivity (IS) based on sensor-augmented-insulin pump (SAP) data in order to customize the insulin to carbohydrate ratio (CR) in adolescents with type 1 diabetes (T1D). Read more about this study
- Who is it for?
- Ages 12 to 21 years
- Conditions the study is for
- Diabetes Mellitus
- What is being tested?
- individualized insulin sensitivity index (ISind)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2019to 1 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age 12-21 year old.
- Clinical diagnosis of T1D ≥1 year
- Treatment with sensor augmented pump therapy (insulin pump + glucose sensor) for at least 1 month
- HbA1c <10%
- Be able to comprehend written and spoken English
Who cannot join
- Pregnancy, breast feeding, or plans to get pregnant for the next 12 months
- On medications that affect insulin sensitivity; has other medical conditions known to affect insulin sensitivity;
- Cognitive impairment
Trial locations and contacts
1 site in 1 country.
United States1 site
Yale Pediatric Diabetes Research Program
New Haven, Connecticut, 06511
About this study
We aim to test the efficacy of a new method for determining individual insulin sensitivity (IS) based on sensor-augmented-insulin pump (SAP) data in order to customize the insulin to carbohydrate ratio (CR) in adolescents with type 1 diabetes (T1D).
To date, the individual insulin sensitivity (IS) could only be investigated by intensive and invasive research techniques that are not feasible to perform in an outpatient setting for pediatric patients with diabetes.
Read more
Recently published studies have demonstrated the efficacy of an algorithm to calculate the patient specific insulin sensitivity to customize the CR for adult patients with T1D. The algorithm has been validated in adult patients, however not yet investigated in the pediatric population with T1D.
The aims of our study are:
- to customize the CR of pediatric subjects with T1D using the individualized insulin sensitivity index (ISind) to improve post-prandial blood glucose control after a standard meal.
- to test, under free living condition (at home), the efficacy of the customized CR in improving post-prandial glycemic control for pediatric subjects with T1D.
This approach would have at least two potential benefits for pediatric patients with T1D:
- To provide a non-invasive tool for individualizing their home insulin therapy;
- To offer a reliable instrument for adjusting the meal bolus of the current hybrid closed loop (HCL) systems to account for the inter-subject variability in insulin action.
Read the detailed description
A new method to assess insulin sensitivity (IS) has been proposed and investigated by the PI and his group at the University of Padova. The new insulin sensitivity index, named "SISP" is calculated from data derived from insulin pump and continuous glucose monitoring (CGM) uploads. The efficiency of the SISP has been tested in-silico using the University of Virginia/Padova T1D simulator by mimicking a single-meal scenario with patient-specific optimized carbohydrate ratio (CR) (increased or decreased by 20%) and optimal CR. In all the simulations the use of the optimal CR, calculated with the proposed method, has improved the overall glycemic control. The simulator (S2013) used for this purpose has been valdated and is approved by the FDA as a substitute for preclinical trials for insulin treatments, including closed-loop algorithms. It is comprised of data from 100 in-silico patients that represent the biological variability of a generic real diabetic population. Thus, an algorithm that is tuned on the basis of in-silico analysis can be safely implemented in real-life setting.
The method to estimate SISP and to optimize the CR from SAP data, could be easily applied to the daily management of patients with T1D and in a closed-loop context since several closed-loop algorithms, currently used in clinical trials, are based on the pre-programmed open-loop insulin therapy.
Once the individualized SISP is calculated, it can be used to customize the CR using the in-silico tested algorithm to determine an individualized CR (CRIND).
Consequently, the CRIND can be tested in outpatient setting safely, and adjusted in a run-to-run framework, using a well described approach of self-learning, the latter allowing titration of the insulin therapy based on CGM data using a self-learning algorithm as previously described.
- Phase 1: "Control period". This phase represents the control frame-time, during which patients, once enrolled, will use their SAP without any adjustment of the CR and correction factors, according to the parameters recorded at the screening visit. This phase is aimed to record the CGM data and will represent the control period of the study. It lasts 3 weeks.
- Phase 2: "Build-up period" This phase is aimed to obtain an adequate amount of data for customizing the insulin pump parameters to the specific features of each subject according to the proposed algorithms. It consists of three standardized meals (Figure 2) and a run-in phase.
Subjects will be randomly assigned to two different pre-meal insulin CR groups in a 1:1 ratio to determine parameters that will be used to adjust the IS algorithm for pediatric patients with T1D. The post-prandial blood glucose pattern after a pre-meal bolus of CR, CR 20% increased, CR 20% decreased are validated parameters necessary to customize the algorithm for a specific patient population with T1D, therefore subjects will be challenged with two different CRs, depending on the randomization, to collect sufficient data to fine tune the algorithm.
Each subject will go through three meal studies;
Group 1. Meal 1: CR with 20% increase; Meal 2: CR home; Meal 3: CR individualized Group 2. Meal 1: CR with 20% decrease; Meal 2: CR home; Meal 3:CR individualized
- Before the 1st meal subjects will be randomly assigned to receive a modified premeal bolus (increased or decreased of 20%, CR+/-20%) in a 1:1 ratio. This change of the home CR (CRHOME) will allow us to estimate the accuracy and error of the CRHOME and to calculate, according to the described algorithm ((21) and below), the optimized CR (CRIND). This latter will be tested in both groups as third meal at home.
- The three meals are followed by a 7 day- run-in period necessary to collect a minimum amount of CGM data to run the algorithm calculations used in the intervention phase. During this period subjects will adopt the CRIND obtained after the standard meals.
- Phase 3: "Intervention period". This phase is aimed to test the efficacy of the CRIND on mitigating post-prandial hyperglycemia by a home-based study, using periodical adjustment of CR and basal rate according to the "run-to-run" approach. It consists of a self-learning algorithm method to adjust insulin regimen (the basal rate and the CRIND) based on CGM post-meal blood glucose patterns and pre-meal insulin bolus.
Subjects will use the SAP tuned according to the individualized ISR2R and CRR2R obtained from the run-in period, along with an individualized insulin basal rate (BasalR2R). During the run-to-run period subjects will receive weekly revised parameters based on run-to-run algorithm according to data analysis of the past seven days. It will last 3 weeks.
- Conditions
- Diabetes Mellitus
- Being tested
- individualized insulin sensitivity index (ISind)
- Keywords
- continuous glucose monitoring
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
individualized insulin sensitivity index (ISind)Other
The new insulin sensitivity index, named "SISP" is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads.
| Study group | Role | What they receive |
|---|---|---|
| All participants | Experimental | +Pediatric patients with T1D. All comparisons will be made within group pre and post intervention. Receives: Other: individualized insulin sensitivity index (ISind) |
What is being measured
The primary outcome is the main question the study is designed to answer.
overall time in target (70-180mg/dl)
the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.
Measured: 4 weeks
Secondary outcomes (34)
median percentage of time spent in hypoglycemia (<70mg/dl) during control period
the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.
Measured: 4 weeks
median percentage of time spent in hypoglycemia (<70mg/dl) post meal 1
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time spent in hypoglycemia (<70mg/dl) post meal 2
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time spent in hypoglycemia (<70mg/dl) post meal 3
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time spent in hypoglycemia (<70mg/dl) during Intervention phase
the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.
Measured: 4 weeks
overall time in target (70-180mg/dl) after meal 1
time in target/180 mins * 100
Measured: 180 minutes post meal
overall time in target (70-180mg/dl) after meal 2
time in target/180 mins * 100
Measured: 180 minutes post meal
overall time in target (70-180mg/dl) after meal 3
time in target/180 mins * 100
Measured: 180 minutes post meal
overall time in target (70-180mg/dl) during Intervention phase
the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.
Measured: 4 weeks
median percentage of time in hyperglycemia (>180mg/dl) during Control Phase
time in target/total time of records using continuous glucose monitoring)*100
Measured: 4 weeks
median percentage of time in hyperglycemia (>180mg/dl) after meal 1
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time in hyperglycemia (>180mg/dl) after meal 2
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time in hyperglycemia (>180mg/dl)after meal 3
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time in hyperglycemia (>180mg/dl) during intervention phase
time in target/total time of records using continuous glucose monitoring)*100
Measured: 4 weeks
median percentage of time below 50mg/dl during control phase
time in target/total time of records using continuous glucose monitoring)*100
Measured: 4 weeks
median percentage of time below 50mg/dl after meal 1
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time below 50mg/dl after meal 2
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time below 50mg/dl after meal 3
time in target/180 mins * 100
Measured: 180 minutes post meal
median percentage of time below 50mg/dl during intervention phase
time in target/total time of records using continuous glucose monitoring)*100
Measured: 4 weeks
severe hypoglycemic events during control phase
They will be measured as number of events per person during the weeks of Control Phase
Measured: 4 weeks
severe hypoglycemic events after meal 1
They will be measured as number of events per person after meal 1 for the entire day
Measured: up to 24 hours
severe hypoglycemic events after meal 2
They will be measured as number of events per person after meal 2 for the entire day
Measured: up to 24 hours
severe hypoglycemic events after meal 3
They will be measured as number of events per person after meal 3 for the entire day
Measured: up to 24 hours
severe hypoglycemic events during intervention phase
They will be measured as number of events per person during the weeks of Intervention Phase.
Measured: 4 weeks
active hypoglycemia correction (carbohydrate intake) during control phase
total number of active events per person during the weeks of Control Phase
Measured: 4 weeks
active hypoglycemia correction (carbohydrate intake) after meal 1
total number of active events per person after meal 1 all day
Measured: up to 24 hours
active hypoglycemia correction (carbohydrate intake) after meal 2
total number of active events per person after meal 2 all day
Measured: up to 24 hours
active hypoglycemia correction (carbohydrate intake) after meal 3
total number of active events per person after meal 3 all day
Measured: up to 23 hours
active hypoglycemia correction (carbohydrate intake) during intervention phase
total number of active events per person during the weeks of Intervention Phase
Measured: 4 weeks
corrective bolus after meal during control phase
total number of active events per person during the weeks of Control Phase vs Intervention Phase
Measured: 4 weeks
corrective bolus after meal 1
total number of active events per person after meal 1 for the entire day
Measured: up to 24 hours
corrective bolus after meal after meal 2
total number of active events per person after meal 2 for the entire day
Measured: up to 24 hours
corrective bolus after meal after meal 3
total number of active events per person after meal 3 for the entire day
Measured: up to 24 hours
corrective bolus after meal during intervention phase
total number of active events per person during the weeks of Intervention Phase
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2017 (estimated)
- Study start1 Oct 2019 (estimated)
- Primary completion1 Jan 2020 (estimated)
- Study completion1 Dec 2022 (estimated)
Why it stopped: Investigator has moved to another institution
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eda Cengiz, MD, Study chair, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03034759
- Sponsor's protocol ID
- 1611018615
- Status last verified
- Jul 2019
- First submitted
- 24 Jan 2017
- Last updated
- 11 Jul 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D
- ClinicalTrials.gov ID
- NCT03034759
- Acronym / sponsor ID
- 1611018615
- Conditions
- Diabetes Mellitus
- Keywords
- continuous glucose monitoring
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Investigator has moved to another institution
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- 1 Oct 2019 (estimated)
- Primary completion
- 1 Jan 2020 (estimated)
- Study completion
- 1 Dec 2022 (estimated)
- First posted
- 27 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We aim to test the efficacy of a new method for determining individual insulin sensitivity (IS) based on sensor-augmented-insulin pump (SAP) data in order to customize the insulin to carbohydrate ratio (CR) in adolescents with type 1 diabetes (T1D).
To date, the individual insulin sensitivity (IS) could only be investigated by intensive and invasive research techniques that are not feasible to perform in an outpatient setting for pediatric patients with diabetes.
Recently published studies have demonstrated the efficacy of an algorithm to calculate the patient specific insulin sensitivity to customize the CR for adult patients with T1D. The algorithm has been validated in adult patients, however not yet investigated in the pediatric population with T1D.
The aims of our study are:
- to customize the CR of pediatric subjects with T1D using the individualized insulin sensitivity index (ISind) to improve post-prandial blood glucose control after a standard meal.
- to test, under free living condition (at home), the efficacy of the customized CR in improving post-prandial glycemic control for pediatric subjects with T1D.
This approach would have at least two potential benefits for pediatric patients with T1D:
- To provide a non-invasive tool for individualizing their home insulin therapy;
- To offer a reliable instrument for adjusting the meal bolus of the current hybrid closed loop (HCL) systems to account for the inter-subject variability in insulin action.
Detailed description
A new method to assess insulin sensitivity (IS) has been proposed and investigated by the PI and his group at the University of Padova. The new insulin sensitivity index, named "SISP" is calculated from data derived from insulin pump and continuous glucose monitoring (CGM) uploads. The efficiency of the SISP has been tested in-silico using the University of Virginia/Padova T1D simulator by mimicking a single-meal scenario with patient-specific optimized carbohydrate ratio (CR) (increased or decreased by 20%) and optimal CR. In all the simulations the use of the optimal CR, calculated with the proposed method, has improved the overall glycemic control. The simulator (S2013) used for this purpose has been valdated and is approved by the FDA as a substitute for preclinical trials for insulin treatments, including closed-loop algorithms. It is comprised of data from 100 in-silico patients that represent the biological variability of a generic real diabetic population. Thus, an algorithm that is tuned on the basis of in-silico analysis can be safely implemented in real-life setting.
The method to estimate SISP and to optimize the CR from SAP data, could be easily applied to the daily management of patients with T1D and in a closed-loop context since several closed-loop algorithms, currently used in clinical trials, are based on the pre-programmed open-loop insulin therapy.
Once the individualized SISP is calculated, it can be used to customize the CR using the in-silico tested algorithm to determine an individualized CR (CRIND).
Consequently, the CRIND can be tested in outpatient setting safely, and adjusted in a run-to-run framework, using a well described approach of self-learning, the latter allowing titration of the insulin therapy based on CGM data using a self-learning algorithm as previously described.
- Phase 1: "Control period". This phase represents the control frame-time, during which patients, once enrolled, will use their SAP without any adjustment of the CR and correction factors, according to the parameters recorded at the screening visit. This phase is aimed to record the CGM data and will represent the control period of the study. It lasts 3 weeks.
- Phase 2: "Build-up period" This phase is aimed to obtain an adequate amount of data for customizing the insulin pump parameters to the specific features of each subject according to the proposed algorithms. It consists of three standardized meals (Figure 2) and a run-in phase.
Subjects will be randomly assigned to two different pre-meal insulin CR groups in a 1:1 ratio to determine parameters that will be used to adjust the IS algorithm for pediatric patients with T1D. The post-prandial blood glucose pattern after a pre-meal bolus of CR, CR 20% increased, CR 20% decreased are validated parameters necessary to customize the algorithm for a specific patient population with T1D, therefore subjects will be challenged with two different CRs, depending on the randomization, to collect sufficient data to fine tune the algorithm.
Each subject will go through three meal studies;
Group 1. Meal 1: CR with 20% increase; Meal 2: CR home; Meal 3: CR individualized Group 2. Meal 1: CR with 20% decrease; Meal 2: CR home; Meal 3:CR individualized
- Before the 1st meal subjects will be randomly assigned to receive a modified premeal bolus (increased or decreased of 20%, CR+/-20%) in a 1:1 ratio. This change of the home CR (CRHOME) will allow us to estimate the accuracy and error of the CRHOME and to calculate, according to the described algorithm ((21) and below), the optimized CR (CRIND). This latter will be tested in both groups as third meal at home.
- The three meals are followed by a 7 day- run-in period necessary to collect a minimum amount of CGM data to run the algorithm calculations used in the intervention phase. During this period subjects will adopt the CRIND obtained after the standard meals.
- Phase 3: "Intervention period". This phase is aimed to test the efficacy of the CRIND on mitigating post-prandial hyperglycemia by a home-based study, using periodical adjustment of CR and basal rate according to the "run-to-run" approach. It consists of a self-learning algorithm method to adjust insulin regimen (the basal rate and the CRIND) based on CGM post-meal blood glucose patterns and pre-meal insulin bolus.
Subjects will use the SAP tuned according to the individualized ISR2R and CRR2R obtained from the run-in period, along with an individualized insulin basal rate (BasalR2R). During the run-to-run period subjects will receive weekly revised parameters based on run-to-run algorithm according to data analysis of the past seven days. It will last 3 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All participants | Experimental | Other: individualized insulin sensitivity index (ISind)+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention. |
Who may qualify
- Ages
- 12 to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Age 12-21 year old.
- Clinical diagnosis of T1D ≥1 year
- Treatment with sensor augmented pump therapy (insulin pump + glucose sensor) for at least 1 month
- HbA1c <10%
- Be able to comprehend written and spoken English
Key exclusion criteria (3 listed)
- Pregnancy, breast feeding, or plans to get pregnant for the next 12 months
- On medications that affect insulin sensitivity; has other medical conditions known to affect insulin sensitivity;
- Cognitive impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| individualized insulin sensitivity index (ISind)The new insulin sensitivity index, named "SISP" is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads. | Other | All participants |
Primary outcome
overall time in target (70-180mg/dl)
Time frame: 4 weeks
the percentage of time in target will be calculated "(time in target/total time of records using continuous glucose monitoring)*100.
34 secondary outcomes
median percentage of time spent in hypoglycemia (<70mg/dl) during control period
Time frame: 4 weeks
median percentage of time spent in hypoglycemia (<70mg/dl) post meal 1
Time frame: 180 minutes post meal
median percentage of time spent in hypoglycemia (<70mg/dl) post meal 2
Time frame: 180 minutes post meal
median percentage of time spent in hypoglycemia (<70mg/dl) post meal 3
Time frame: 180 minutes post meal
median percentage of time spent in hypoglycemia (<70mg/dl) during Intervention phase
Time frame: 4 weeks
overall time in target (70-180mg/dl) after meal 1
Time frame: 180 minutes post meal
overall time in target (70-180mg/dl) after meal 2
Time frame: 180 minutes post meal
overall time in target (70-180mg/dl) after meal 3
Time frame: 180 minutes post meal
overall time in target (70-180mg/dl) during Intervention phase
Time frame: 4 weeks
median percentage of time in hyperglycemia (>180mg/dl) during Control Phase
Time frame: 4 weeks
median percentage of time in hyperglycemia (>180mg/dl) after meal 1
Time frame: 180 minutes post meal
median percentage of time in hyperglycemia (>180mg/dl) after meal 2
Time frame: 180 minutes post meal
median percentage of time in hyperglycemia (>180mg/dl)after meal 3
Time frame: 180 minutes post meal
median percentage of time in hyperglycemia (>180mg/dl) during intervention phase
Time frame: 4 weeks
median percentage of time below 50mg/dl during control phase
Time frame: 4 weeks
median percentage of time below 50mg/dl after meal 1
Time frame: 180 minutes post meal
median percentage of time below 50mg/dl after meal 2
Time frame: 180 minutes post meal
median percentage of time below 50mg/dl after meal 3
Time frame: 180 minutes post meal
median percentage of time below 50mg/dl during intervention phase
Time frame: 4 weeks
severe hypoglycemic events during control phase
Time frame: 4 weeks
severe hypoglycemic events after meal 1
Time frame: up to 24 hours
severe hypoglycemic events after meal 2
Time frame: up to 24 hours
severe hypoglycemic events after meal 3
Time frame: up to 24 hours
severe hypoglycemic events during intervention phase
Time frame: 4 weeks
active hypoglycemia correction (carbohydrate intake) during control phase
Time frame: 4 weeks
active hypoglycemia correction (carbohydrate intake) after meal 1
Time frame: up to 24 hours
active hypoglycemia correction (carbohydrate intake) after meal 2
Time frame: up to 24 hours
active hypoglycemia correction (carbohydrate intake) after meal 3
Time frame: up to 23 hours
active hypoglycemia correction (carbohydrate intake) during intervention phase
Time frame: 4 weeks
corrective bolus after meal during control phase
Time frame: 4 weeks
corrective bolus after meal 1
Time frame: up to 24 hours
corrective bolus after meal after meal 2
Time frame: up to 24 hours
corrective bolus after meal after meal 3
Time frame: up to 24 hours
corrective bolus after meal during intervention phase
Time frame: 4 weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2019.
Related trials for Diabetes Mellitus
Active, not recruitingPhase 2
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
Diabetic Kidney Disease (DKD), Type 2 Diabetes
Active, not recruitingPhase 3
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Type 1 Diabetes
Recruiting
Culturally Tailored Program for Food-Insecure Adults: SPICE-D
Type 2 Diabetes Mellitus (T2D)
RecruitingPhase 2
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Trauma, Hemorrhage
RecruitingObservational study
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eda Cengiz, MD study chair
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing individualized insulin sensitivity index (ISind) in people with Diabetes Mellitus, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 11 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall time in target (70-180mg/dl) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2019.